Osseous spinal metastases are secondary malignant tumor deposits involving the vertebral bodies, pedicles, posterior elements, and/or epidural space. The spine is the most common skeletal site of metastatic disease. Bone metastases occur frequently during the course of advanced malignancy, and the vertebral column is particularly susceptible because of its rich vascular supply and extensive venous plexus.
According to their predominant radiographic phenotype, spinal metastases are classified into three principal patterns:
A particularly serious complication is metastatic spinal cord compression (MSCC), in which epidural tumor extension and/or pathological vertebral collapse compromises the spinal cord or cauda equina. MSCC can result in irreversible neurological deficits and constitutes an oncological emergency.
Frequency and characteristic pattern of spinal involvement according to primary malignancy:
The clinical presentation of spinal metastatic disease depends on the anatomical level, tumor burden, extent of osseous destruction, spinal stability, epidural extension, and degree of neurological involvement. Multiple symptoms are frequently present simultaneously.
Metastatic spinal cord compression is an oncological emergency. New or progressive motor weakness, bladder dysfunction, rapidly worsening back pain, or other signs of spinal cord or cauda equina compromise require urgent MRI assessment and immediate initiation of an appropriate treatment pathway. Neurological outcome is strongly dependent on neurological function at the time treatment begins; early recognition and intervention are therefore essential.
The diagnostic work-up of suspected spinal metastatic disease has three principal objectives:
confirmation and characterization of metastatic involvement, assessment of mechanical spinal stability and neurological risk, and definition of the optimal individualized treatment strategy. Multimodal imaging is generally required.
The Spinal Instability Neoplastic Score (SINS) is a validated framework for evaluating tumor-related mechanical instability. It integrates six clinical and radiographic parameters and yields a total score from 0 to 18:
Management of spinal metastases is multidisciplinary and is determined by the primary malignancy, histology, systemic disease burden, mechanical stability, degree of epidural spinal cord compression, neurological status, previous treatments, and the patient's overall clinical condition. Several modalities are frequently combined.
Spine stereotactic body radiotherapy (spine SBRT) is an evidence-based treatment modality for appropriately selected spinal metastases. It enables delivery of an ablative radiation dose to the metastatic target while maintaining strict dose constraints for the spinal cord, cauda equina, and other adjacent organs at risk.
The high spatial accuracy of the CyberKnife® system permits steep dose gradients immediately adjacent to the spinal cord. Continuous X-ray-based image guidance enables real-time verification and correction of spinal target position throughout treatment, providing submillimeter targeting precision without the need for invasive fixation.
Spinal cord dose constraints are determined according to fractionation, prior radiation exposure, treatment volume, and contemporary tolerance data. These constraints are incorporated rigorously into individualized treatment planning to minimize the risk of radiation-induced myelopathy.
No. Suitability for spine SBRT depends on several factors:
High-grade epidural spinal cord compression, particularly Bilsky/ESCC grade 3, generally requires surgical evaluation and often decompression or separation surgery before high-dose CyberKnife treatment can be safely delivered. The most favorable candidates for primary spine SBRT are patients with low-grade epidural disease and a mechanically stable or only potentially unstable spine, provided that multidisciplinary assessment confirms treatment safety.
Clinically meaningful pain relief frequently begins within approximately 1–4 weeks after treatment. Published studies of spine SBRT report substantial pain improvement in a large proportion of appropriately selected patients. During the first several days after irradiation, a transient pain flare may occur as a result of treatment-related inflammatory change or edema. This is usually self-limiting and can be managed with analgesics and, where clinically appropriate, corticosteroids.
In many cases, one to three involved vertebral levels can be treated within the same CyberKnife treatment course. Spatially separate lesions may also be treated as multiple targets when technically and dosimetrically appropriate. In more extensive spinal metastatic disease, the optimal strategy is individualized within the multidisciplinary tumor board and may combine SBRT with systemic therapy, surgery, or conventional radiotherapy to other involved regions.
Yes, in many carefully selected patients. Re-irradiation requires detailed reconstruction of the previous radiation dose and calculation of the cumulative biologically relevant dose to the spinal cord or thecal sac and other organs at risk. The conformality and steep dose gradients achievable with CyberKnife can permit focal salvage re-irradiation while limiting additional neural-tissue exposure. Every spinal re-irradiation case requires individualized dosimetric assessment and multidisciplinary review.
Radiation-induced myelopathy is a rare but potentially serious complication. With contemporary stereotactic treatment planning, accurate image guidance, appropriate fractionation, and strict adherence to validated spinal cord or thecal sac dose constraints, the risk is very low. The precision of CyberKnife is particularly valuable because a steep dose gradient can be created at the interface between the metastatic target and the spinal cord, allowing an effective tumor dose while respecting neural-tissue tolerance.
The increasing complexity of contemporary treatment options means that therapeutic decisions should always be made in the context of the patient's individual oncological situation, functional status, quality of life, and personal circumstances. We consider it essential that patients, their families, and those supporting them understand the nature of the disease and the available treatment strategies.
Together with our medical partners, we can involve specialists from all disciplines required for individualized diagnostic assessment and treatment. Our team is committed to providing coordinated, comprehensive care from the first contact with the ERCM.
For treatment enquiries, please use our contact form. You may also contact us by telephone during our opening hours or via our social media channels. Each enquiry is reviewed individually and processed promptly.